Peripheral Vascular Disease Clinical Trial
Official title:
Adjuvant Benefit of Neuromuscular Electrical Stimulation to Supervised Exercise in Patients With Intermittent Claudication
This study will assess the adjuvant benefit of a neuromuscular electrical stimulation device to standard treatment of supervised exercise in patients suffering from symptoms and effects of lower limb Intermittent Claudication.
The circulation of blood around the body is dependent on effective pumping of the heart.
Patients with claudication experience pain or discomfort in their legs usually during
activity such as walking, which goes away at rest. Claudication is a symptom of peripheral
arterial disease (PAD). If left untreated, patients can develop arterial insufficiency which
can lead to various complications such as swelling, painful legs, reduced healing of injuries
and the loss of limbs in extreme conditions.
PAD can be defined as a narrowing of the arteries reducing blood flow. It is most commonly
due to atherosclerosis, and has associations with heart disease, stroke, and diabetes. Its
incidence is estimated at 7-14% in the general population, increasing with age to about 20%
in the over-seventies. It is associated with effects on mobility, skin condition and quality
of life. Symptoms include pain in the legs on walking (intermittent claudication), pain at
rest (particularly at night), gangrene, and limb loss. Management of PAD is based on
encouraging exercise, and modification of risk factors such as smoking, high blood pressure,
high cholesterol and diabetes.
In patients with PAD, exercise tolerance is often limited. Severe symptoms and disease can be
treated by procedures such as balloon angioplasty, stenting or surgical bypass, but these
procedures have risks. There also remains a percentage of patients who are not suitable for
revascularisation, and have few options besides amputation available to them.
Current NICE guidelines (NICE Clinical Guideline 147: Lower Limb Peripheral Arterial
Disease:Diagnosis and Management guidance.nice.org.uk/cg147) advise a supervised exercise
programme should be offered to all patients with IC as well as best medical therapy. Regular
exercise has shown to significantly improve symptoms of IC in patients, but the effects of
this benefit quickly revert upon inactivity.
Some trials have shown that increasing the blood flow in the legs over time using medical
devices (intermittent pneumatic compression, muscle stimulators), in addition to maximal
medical and surgical therapy, can increase claudication distance, absolute walking distance,
decrease rest pain, and reduce amputation rates. In our unit it has become apparent that
there are an increasing number of medical devices available for circulatory support, either
for use as an inpatient, out-patient, or a member of the general public. The supporting
evidence for these is variable in scientific and clinical content or relevance, and requires
clinical trials to evaluate further.
The device being used in this study activates the pumping action of the leg muscles by
providing neuromuscular electrical stimulation (NMES) to cause foot muscle contraction and
relaxation. This squeezes blood back towards the heart, improving circulation.
The investigators wish to evaluate whether NMES using this device has the same beneficial
effects in patients with claudication when used in conjunction with supervised exercise.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05335525 -
Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
|
||
Active, not recruiting |
NCT01903044 -
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating
|
Phase 1/Phase 2 | |
Completed |
NCT02271529 -
Zilver PTX Delivery System
|
N/A | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Recruiting |
NCT02054871 -
RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Completed |
NCT00574782 -
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
|
N/A | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Completed |
NCT01355406 -
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
|
N/A | |
Recruiting |
NCT05804097 -
Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
|
Phase 4 | |
Recruiting |
NCT03638115 -
The VaSecure BTK Study
|
N/A | |
Active, not recruiting |
NCT03241459 -
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
|
N/A | |
Active, not recruiting |
NCT01661231 -
Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe
|
N/A | |
Completed |
NCT01722877 -
JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
|
N/A | |
Completed |
NCT01444378 -
Absolute Pro® MOMENTUM™
|
N/A | |
Completed |
NCT00753337 -
The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
|
N/A | |
Completed |
NCT00538226 -
Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg
|
Phase 1 | |
Completed |
NCT00593385 -
Atrium iCAST Iliac Stent Pivotal Study
|
N/A | |
Recruiting |
NCT00385385 -
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
|
Phase 2 | |
Completed |
NCT00392509 -
ALD-301 for Critical Limb Ischemia, Randomized Trial
|
Phase 1/Phase 2 |